BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American:…
ZUG, Switzerland, and BOSTON, July 26, 2023 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS)…
ZUG, Switzerland, and BOSTON, July 26, 2023 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS)…
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) — Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today…
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) — Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today…
Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in…
Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in…
-Top-line results planned to be released in third quarter 2023- -Trial results are intended to…
-Top-line results planned to be released in third quarter 2023- -Trial results are intended to…
MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy…
ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy…
DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN)…
DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN)…
Conference call scheduled for 8:00 a.m. Eastern Time WALTHAM, Mass., July 26, 2023 (GLOBE NEWSWIRE)…
Conference call scheduled for 8:00 a.m. Eastern Time WALTHAM, Mass., July 26, 2023 (GLOBE NEWSWIRE)…
SOUTH ORANGE, NJ, July 26, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Nephros, Inc. (Nasdaq:…
SOUTH ORANGE, NJ, July 26, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Nephros, Inc. (Nasdaq:…
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical…